These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 24944508)
1. Optimization of biguanide derivatives as selective antitumor agents blocking adaptive stress responses in the tumor microenvironment. Narise K; Okuda K; Enomoto Y; Hirayama T; Nagasawa H Drug Des Devel Ther; 2014; 8():701-17. PubMed ID: 24944508 [TBL] [Abstract][Full Text] [Related]
2. Development of antitumor biguanides targeting energy metabolism and stress responses in the tumor microenvironment. Sakai T; Matsuo Y; Okuda K; Hirota K; Tsuji M; Hirayama T; Nagasawa H Sci Rep; 2021 Mar; 11(1):4852. PubMed ID: 33649449 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of antitumor activity in Pseudolaric acid B Azole derivatives: Novel and potent angiogenesis inhibitor via regulation of the PI3K/AKT and MAPK mediated HIF-1/VEGF signaling pathway. Deng H; Xu Q; Li XT; Huang X; Liu JY; Yan R; Quan ZS; Shen QK; Guo HY Eur J Med Chem; 2024 Nov; 278():116813. PubMed ID: 39226705 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity in vivo. Luo K; Bao Y; Liu F; Xiao C; Li K; Zhang C; Huang R; Lin J; Zhang J; Jin Y Eur J Med Chem; 2019 Oct; 179():805-827. PubMed ID: 31295714 [TBL] [Abstract][Full Text] [Related]
5. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors. Kim HS; Hong M; Lee SC; Lee HY; Suh YG; Oh DC; Seo JH; Choi H; Kim JY; Kim KW; Kim JH; Kim J; Kim YM; Park SJ; Park HJ; Lee J Eur J Med Chem; 2015 Nov; 104():157-64. PubMed ID: 26457742 [TBL] [Abstract][Full Text] [Related]
7. Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: synthesis, anti-invasive and anti-angiogenic properties. Wang L; Chen G; Lu X; Wang S; Han S; Li Y; Ping G; Jiang X; Li H; Yang J; Wu C Eur J Med Chem; 2015 Jan; 89():88-97. PubMed ID: 25462229 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of 3-(phenylethynyl)-1,1'-biphenyl-2-carboxylate derivatives as new HIF-1 inhibitors. Wang S; Wang X; Shao Y; Shao K; Wang Y; Guo X; Dong H; Zhao W; Li Y; Li G Bioorg Chem; 2021 Nov; 116():105298. PubMed ID: 34454298 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway. Shang FF; Wang JY; Xu Q; Deng H; Guo HY; Jin X; Li X; Shen QK; Quan ZS Eur J Med Chem; 2021 Aug; 220():113474. PubMed ID: 33930802 [TBL] [Abstract][Full Text] [Related]
10. Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound. Park K; Lee HE; Lee SH; Lee D; Lee T; Lee YM Oncotarget; 2017 Jan; 8(5):7801-7813. PubMed ID: 27999195 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of asymmetric dimeric β-carboline derivatives as potential antitumor agents. Guo L; Chen W; Cao R; Fan W; Ma Q; Zhang J; Dai B Eur J Med Chem; 2018 Mar; 147():253-265. PubMed ID: 29448140 [TBL] [Abstract][Full Text] [Related]
12. 6-Amino-2,4,5-trimethylpyridin-3-ols: a new general synthetic route and antiangiogenic activity. Kim DG; Kang Y; Lee H; Lee EK; Nam TG; Kim JA; Jeong BS Eur J Med Chem; 2014 May; 78():126-39. PubMed ID: 24681390 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols. Lee H; Banskota S; Kim DG; Been JH; Jin YJ; Gautam J; Jang H; Nam TG; Kim JA; Jeong BS Bioorg Med Chem Lett; 2014 Jul; 24(14):3131-6. PubMed ID: 24894557 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, Anticancer Activities, and Mechanism of N-heptyl-containing Biguanide Derivatives. Wang W; Xiao D; Zhou S; Xu S; Tang X; Zhou X; Liu J; Xu C; Peng M; Yang X Med Chem; 2022; 18(8):895-902. PubMed ID: 35142271 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel N Guo L; Ma Q; Chen W; Fan W; Zhang J; Dai B J Enzyme Inhib Med Chem; 2019 Dec; 34(1):375-387. PubMed ID: 30734606 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors. Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993 [TBL] [Abstract][Full Text] [Related]
20. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Sonawane V; Rathos MJ; Kumar S; Joshi KS BMC Cancer; 2011 Aug; 11():338. PubMed ID: 21819554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]